---
title: "Ladenburg Thalmann & Co. Keeps Their Buy Rating on Turn Therapeutics Inc (TTRX)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295825793.md"
description: "Ladenburg Thalmann & Co. analyst Rick Bienkowski maintained a Buy rating on Turn Therapeutics Inc (TTRX) with a $16.00 price target. This aligns with the general market consensus, which also rates TTRX as a Moderate Buy with an average price target of $16.00."
datetime: "2026-08-13T16:35:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295825793.md)
  - [en](https://longbridge.com/en/news/295825793.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295825793.md)
generator: "portal-rs"
---

# Ladenburg Thalmann & Co. Keeps Their Buy Rating on Turn Therapeutics Inc (TTRX)

In a report released today, Rick Bienkowski from Ladenburg Thalmann & Co. maintained a Buy rating on Turn Therapeutics Inc, with a price target of $16.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

According to TipRanks, Bienkowski is an analyst with an average return of -23.0% and a 21.88% success rate.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Turn Therapeutics Inc with a $16.00 average price target.

### Related Stocks

- [TTRX.US](https://longbridge.com/en/quote/TTRX.US.md)

## Related News & Research

- [Turn Therapeutics sells 135,000 shares in private placement for $1.35 million](https://longbridge.com/en/news/296141997.md)
- [Turn Therapeutics says mouse study shows GX-03 cuts dermatitis severity 66%](https://longbridge.com/en/news/296487429.md)
- [Barclays Reaffirms Their Buy Rating on Airbus Group SE (EADSF)](https://longbridge.com/en/news/297615153.md)
- [Barclays Sticks to Their Buy Rating for Ryanair Holdings (RYA)](https://longbridge.com/en/news/297609577.md)
- [Analyst Maintains Buy Rating on Teladoc with Unchanged $10.50 Price Target Amid Strategic Transition and New CFO Appointment](https://longbridge.com/en/news/297585950.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**